The dominant TNFR2 antagonists from the study of Torrey et al. (2017) preferentially suppressed the activity of tumor-associated Tregs but had no or only minor inhibitory effects on regular Tregs in the periphery, which play a crucial role in the maintenance of immunological homeostasis. This evidence concerns the gene TNFRSF1B and neoplasm.